Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Free Cash Flow (2023 - 2025)

Compass Therapeutics' Free Cash Flow history spans 3 years, with the latest figure at -$13.3 million for Q4 2025.

  • For Q4 2025, Free Cash Flow fell 44.66% year-over-year to -$13.3 million; the TTM value through Dec 2025 reached -$49.2 million, down 9.51%, while the annual FY2025 figure was -$49.2 million, 9.51% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$13.3 million at Compass Therapeutics, down from -$10.9 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$5.9 million in Q3 2023 and bottomed at -$13.9 million in Q1 2024.
  • The 3-year median for Free Cash Flow is -$11.5 million (2024), against an average of -$11.2 million.
  • The largest YoY upside for Free Cash Flow was 25.89% in 2024 against a maximum downside of 87.04% in 2024.
  • A 3-year view of Free Cash Flow shows it stood at -$12.4 million in 2023, then grew by 25.89% to -$9.2 million in 2024, then tumbled by 44.66% to -$13.3 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Free Cash Flow are -$13.3 million (Q4 2025), -$10.9 million (Q3 2025), and -$11.8 million (Q2 2025).